Role of resveratrol in modulating microRNAs in human diseases: From cancer to inflammatory disorder

(E-pub Abstract Ahead of Print)

Author(s): Atefeh Amiri, Maryam Mahjoubin Tehran, Zatollah Asemi, Alimohammad Shafiee, Sarah Hajighadimi, Sanaz Moradizarmehri, Hamid Reza Mirzaei*, Hamed Mirzaei*.

Journal Name: Current Medicinal Chemistry

Abstract:

Cancer and inflammatory disorders are two important public health issues worldwide with significant socio‐economic impacts. Despite several efforts, the current therapeutic platforms are associated with severe limitations. Therefore, developing new therapeutic strategies for the treatment of these diseases is a top priority. Besides current therapies, the utilization of natural compounds has emerged as a new horizon for the treatment of cancer and inflammatory disorders as well. Such natural compounds could be used either alone or in combination with the standard cancer therapeutic modalities such as chemotherapy, radiotherapy, and immunotherapy. Resveratrol is a polyphenolic compound that is found in grapes as well as other foods. It has been found that this medicinal agent displays a wide pharmacological spectrum including anti-cancer, anti-inflammatory, anti-microbial, and antioxidant activities. Recently clinical and pre-clinical studies have highlighted the anti-cancer and anti-inflammatory effects of resveratrol. Increasing evidence revealed that resveratrol exerts its therapeutic effects by targeting various cellular and molecular mechanisms. Among cellular and molecular targets that are modulated by resveratrol, microRNAs (miRNAs) have appeared as key targets. MiRNAs are short non-coding RNAs that act as epigenetic regulators. These molecules are involved in many processes that are involved in the initiation and progression of cancer and inflammatory disorders. Herein, we summarized various miRNAs that are directly/indirectly influenced by resveratrol in cancer and inflammatory disorders.

Keywords: Resveratrol, MicroRNA, Cancer, Therapy, Non-coding RNAs, Non-cancerous Diseases

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/0929867326666191212102407
Price: $95



Resveratrol: A new potential therapeutic agent for melanoma?

(E-pub Abstract Ahead of Print)

Author(s): Mohamad Hossein Pourhanifeh, Kazem Abbaszadeh-Goudarzi, Mohammad Goodarzi, Sara G.M. Piccirillo, Alimohammad Shafiee, Sarah Hajighadimi, Sanaz Moradizarmehri, Zatollah Asemi*, Hamed Mirzaei*.

Journal Name: Current Medicinal Chemistry

Abstract:

Melanoma is the most life-threatening and aggressive class of skin malignancies. The incidence of melanoma has steadily increased. Metastatic melanoma is greatly resistant to standard anti-melanomatreatments such as chemotherapy, and 5-year survival rate of cases with melanoma who have metastatic form of disease is less than 10%. The contributing role of apoptosis, angiogenesis and autophagy in the pathophysiology of melanoma has been previously demonstrated. Thus, it is extremely urgent to search for complementary therapeutic approachesthat couldenhance the quality of life of subjects and reduce treatment resistance and adverse effects. Resveratrol, known as a polyphenol component present in grapes and some plants, has anti-cancer properties due to its function as an apoptosis inducer in tumor cells, and anti-angiogenic agent to prevent metastasis. However, more clinical trials should be conducted to prove resveratrol efficacy.

Herein, for first time, we summarize current knowledge of anti-cancerous activities of resveratrol in melanoma.

Keywords: Melanoma, Resveratrol, Therapy, Natural compounds, Apoptosis, Angiogenesis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/0929867326666191212101225
Price: $95



Chilling-Like Attacks Terminated by Slow Pathway Ablation

(E-pub Abstract Ahead of Print)

Author(s): Gulay Yetkin, Selcuk Ozturk, Ertan Yetkin*.

Journal Name: Current Cardiology Reviews

Abstract:

Symptoms of patients or the way of presenting complaints by the patients may be indefinite, obscure or misleading for the diagnosis of supraventricular tachycardia. The content of the history shows variability depending on the presenting symptoms, patient concerns and priority. Herein, we report an unusual case of a young woman suffering from chilling-like attacks for one and half years and treated by slow pathway ablation.

Keywords: Chilling, Infection, Supraventricular tachycardia, Slow pathway ablation, Malaria

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1573403X15666191212100050
Price: $95



Identification of Key Features of CNS Drugs Based on SVM and Greedy Algorithm

(E-pub Abstract Ahead of Print)

Author(s): Ruilin Zhang, Yanrui Ding*.

Journal Name: Current Computer-Aided Drug Design

Abstract:

Introduction: The research and development of drugs related to central nervous system (CNS) diseases is a long and arduous process with high cost, long cycle and low success rate. Identification of key features based on available CNS drugs is of great significance for the discovery of new drugs.

Materials and Methods: In this paper, based on the PaDEL descriptors of CNS drugs and non-CNS drugs, a support vector machine (SVM) model was constructed to identify the key features of CNS drugs. Firstly, the random forest algorithm was used to rank descriptors according to the feature significance that contributes to the identification of CNS drugs. Then, a reliable SVM model was constructed, and the optimal combination of descriptors was determined based on greedy algorithm and recursive feature elimination method.

Results and Conclusion: It was found, based on the optimal combination of 40 descriptors, the prediction accuracy of CNS drugs and non-CNS drugs reached 94.2% and 94.4% respectively. nF11HeteroRing, AATSC3v, SpMin6_Bhi, maxdssC, AATS4v, E1v, E3e, GATS5s, minsOH and minHBint4 are the key features to distinguish between CNS drugs and non-CNS drugs.

Keywords: CNS drugs, Support vector machine, Greedy algorithm, Key features, Drug identification, Blood-brain barrier

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1573409915666191212095340
Price: $95



Microbial Biosurfactants- An Ecofriendly Boon To Industries For Green Revolution

(E-pub Abstract Ahead of Print)

Author(s): Pushpinder Sharma, Nivedita Sharma*.

Journal Name: Recent Patents on Biotechnology

Abstract:

Biosurfactants have biological origin that are widely known as surface active agents. Different classes of biosurfactant has high importance in both the biotechnological and microbiological arena. Pseudomonas aeruginosa, Bacillus subtilis and Candida sp. are important classes of microorganisms that are highly investigated for the production of rhamnolipids (RLs) biosurfactants. Rhamnolipids have unique surface activity and gained interest in various industrial applications. Due to their high biodegradability, renewability and functionally maintenance at extreme conditions microbial biosurfactants are more advantageous than chemical based biosurfactants. Biosurfactants produced by microorganisms are potential candidate for the biodegradation, environmental cleanup of pollutants and also has some role in the heavy metal removal of metallurgical industries. Therefore, a greater attention has been paid on biosurfactants and identifying their potential applications for further studies.

Keywords: Rhamnolipids (RLs), Biosurfactant, Pseudomonas aeruginosa, Biodegradation

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1872208313666191212094628
Price: $95


Current Molecular Medicine

Editors-in-Chief:

David W. Li (China)
Andras Guttman (Hungary)

Back


Is hepatitis B surface antigen (HB s Ag) enough alone as a screening test for HBV infection in rheumatic disease patients before starting immunosuppressive therapies? A cross sectional study.

(E-pub Abstract Ahead of Print)

Author(s): Rasha Abdel-Noor, Mona Watany, Sherief Abd-Elsalam*, Walaa ElKhalawany, Shaimaa Soliman, Rehab Badawi.

Journal Name: Infectious Disorders - Drug Targets
(Formerly Current Drug Targets - Infectious Disorders)

Abstract:

Background & objectives: Prevalence of hepatitis B virus in patients with rheumatic diseases has been reported differently among studies. The loss of immune control in these patients may result in the reactivation of HBV replication within hepatocytes. Considering the lifelong use of multiple anti-rheumatic drugs, screening for HBV is recommended before starting immunosuppressive or immunomodulatory therapy. The aim of this study was to select the best and simplest test for screening of HBV in rheumatic patients.

Methods: This study was carried out on 102 patients with different rheumatic diseases. Screening to all patients by hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and human immune deficiency virus antibodies (HIV) were done. HBV core antibodies and real time PCR to detect HBV DNA were done.

Results: The mean age of the patients was 37.18 ± 12.37 years, 3.9% of them were males and 96.1% were females. HBsAg had 100% Sensitivity, 100% Specificity, 100% PPV, 100% NPV and 99.0% accuracy. While, anti-HBc had 100% Sensitivity, 78% Specificity, 8% PPV, 100% NPV and 78% accuracy in screening of HBV.

Conclusions: HBs Ag was found to be superior to antiHBc for screening for HBV infection in rheumatic patients.

Keywords: HBV, HBs-antigen, HBc-antibodies, Screening, Rheumatic disease, Immunosuppressive therapy

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1871526519666191212094141
Price: $95



Effects of N-acetylcysteine on Pulmonary Functions in Patients with Systemic Sclerosis: A double blind, placebo controlled study

(E-pub Abstract Ahead of Print)

Author(s): Samrad Mehrabi*, Maryam Mazidi Moradi, Zohre Khodamoradi, Mohammad Ali Nazarinia.

Journal Name: Current Rheumatology Reviews

Abstract:

Background: Systemic sclerosis (SSc) is a systematic and rare autoimmune disease that affects many organs. N-acetylcysteine (NAC), thiol containing compound, can act both as the precursor of reduced glutathione and direct scavenger of reactive oxygen species.

Objects: We assessed the clinical effect of NAC on pulmonary function test of patients with diffuse scleroderma. Methods: This study is a randomized double blind clinical trial that was done on 25 patients with diffuse SSc without lung involvement on primary chest high-resolution computed tomography. Placebo was administered for 13 patients and 1200 milligram NAC for 12 patients. Body plethysmography parameters were assessed at the beginning of the study and after 24 weeks.

Results: Patients in the two groups were matched in the basic demographic data like age, duration of disease, and modified Rodnan skin score. The analysis showed no significant differences in parameters of plethysmography between the two groups. After importing the data of 2 patients in the placebo-treated group, who developed interstitial lung disease, DLCO in the placebo-treated group was 90.69 ± 21.29 milliliter at the end of the study, which significantly decreased compared with the beginning of the study (102.30 ± 13.83 ml). Also, changes of DLCO between the two groups were significantly different.

Conclusions: In this trial, sensitivity of DLCO as the first marker in evaluation of pulmonary function in patients with SSc was confirmed. On the other hand, NAC had no effect versus placebo in a period of 24 weeks.

Keywords: Systemic sclerosis, Scleroderma, Interstitial lung disease, Pulmonary function test, N-acetyl cysteine, Clinical trial

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1573397115666191212092608
Price: $95



Cardiovascular Risk Assessment in People Living With HIV: A Systematic Review and Meta-Analysis from Real-Life Data.

(E-pub Abstract Ahead of Print)

Author(s): Marina Grand*, Daniel Bia, Alejandro Diaz.

Journal Name: Current HIV Research

Abstract:

Background: People living with HIV (PLWHIV) have a 2-fold higher risk of having a cardiovascular event than HIV-negative individuals.

Objectives: To estimate the pooled proportion of moderate-high cardiovascular risk in PLWHIV obtained through different scores. In addition, to establish the prevalence of dyslipidemia, smoking habit, diabetes and high blood pressure in the studies included.

Methods: A bibliographic search was conducted in MEDLINE from studies on cardiovascular risk assessment in PLWHVI that took place during the period of inception to July 2018. Eligibility criteria for inclusion were: cross-sectional or longitudinal studies in HIV-positive adults in which prevalence of moderate-high cardiovascular risk (or data to calculate it) was reported, and include at least one of the following cardiovascular risk scores: Framingham, ASCVD, D:A:D, Progetto Cuore, PROCAM, SCORE, Regicor, World Health Organization scores.

Results: Bibliographic search identified 278 studies. Finally, thirty-nine peer-reviewed publications were identified for a collective total of 13698 subjects. The pooled prevalence of moderate-high cardiovascular risk in PLWHIV obtained with nine different scores through random-effect modeling was 20.41% (95% CI: 16.77-24.31). The most prevalent concomitant cardiovascular risk factor was dyslipidemia (39.5%), smoking (33.0 %), high blood pressure (19.8%) and diabetes (7.24%).

Conclusions: Data obtained in this systematic review indicate that more than 1 in every five subjects with HIV had a moderate-high cardiovascular risk. In consequence, the burden of cardiovascular disease in PLWHIV represents a public health problem. There is an urgent need to develop strategies to prevent and detect cardiovascular risk assessment effectively in PLWHIV.

Keywords: Cardiovascular risk, Risk assessment, Human immunodeficiency virus, Systematic review, Meta-analysis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1570162X17666191212091618
Price: $95



Novel Findings and Therapeutic Targets in Cardioprotection

Author(s): Hao Jiang, Aijun Sun.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 35 , 2019

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 35
Year: 2019
Page: [3703 - 3703]
Pages: 1
DOI: 10.2174/138161282535191211155115